{"product_id":"olainfarm-business-model-canvas","title":"Olainfarm Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnlock the strategic Business Model Canvas to map value creation, growth, and revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the full strategic blueprint behind Olainfarm’s business model with our detailed Business Model Canvas—three concise sentences show how the company creates value, scales operations, and secures revenues across markets. Ideal for investors, consultants, and entrepreneurs seeking actionable insight. Purchase the full editable Canvas to benchmark, plan, and present with confidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAPI and raw material suppliers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs of 2024 Olainfarm relies on secure, EU GMP-compliant API and raw material suppliers to ensure uninterrupted feedstock for finished dosage forms and intermediates. Multi-sourcing and routine quality audits reduce supply risk and variability. Strategic agreements lock in volumes and prices, while long-term partnerships enable pipeline scaling and new launches.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCROs, CMOs, and research institutes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eExternal CROs, CMOs and research institutes accelerate Olainfarm’s preclinical, clinical and scale-up work; the global CRO market reached about $66 billion in 2024, while the CDMO market was ~ $23 billion in 2024, enabling access to specialized trial capabilities, geographic reach and flexible capacity for peak loads and niche technologies; academic ties fuel innovation in CNS, cardiovascular and anti-infective pipelines.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory bodies and notified organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eClose collaboration with EU and target-market regulators accelerates approvals and variations, leveraging EMA centralized procedure timelines (median review 210 days) to reduce time-to-market. Ongoing dialogue ensures compliance with GMP, GCP and pharmacovigilance standards; inspections and certifications validate quality systems for global markets, lowering recall risk through proactive engagement.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDistributors, wholesalers, and pharmacy chains\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDistribution partners extend Olainfarm reach across the Baltics, CEE and export markets, handling last-mile logistics, inventory management and in-market activation; structured data sharing with distributors improves demand forecasting and service levels; co-marketing agreements boost shelf presence and promotional support for OTC and Rx lines.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGeographic reach: Baltics, CEE, export markets\u003c\/li\u003e\n\u003cli\u003eOperations: last-mile, inventory, activation\u003c\/li\u003e\n\u003cli\u003eData: shared forecasting, service uplift\u003c\/li\u003e\n\u003cli\u003eCommercial: co-marketing for OTC\/Rx\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospitals, clinics, and key opinion leaders\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eClinical partnerships drive real-world evidence generation and formulary inclusion, while key opinion leaders bolster scientific credibility across target therapeutic areas. Joint programs with hospitals and KOLs align guidelines and scale physician education, and hospital networks enable tender participation and faster product adoption, with tenders representing ~60% of institutional drug procurement in EU markets in 2024.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRWE-driven formulary access\u003c\/li\u003e\n\u003cli\u003eKOL endorsement for credibility\u003c\/li\u003e\n\u003cli\u003eGuideline-aligned education programs\u003c\/li\u003e\n\u003cli\u003eTender-enabled adoption (~60% EU institutional procurement 2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEU pharma partnerships secure API, R\u0026amp;D and tenders; regulators \u003cstrong\u003e210 days\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOlainfarm partners with EU GMP API suppliers, CROs\/CDMOs and distributors to secure feedstock, R\u0026amp;D capacity and market access; global CRO market $66B and CDMO $23B in 2024. Regulatory ties leverage EMA median review 210 days to speed approvals. Tenders drive uptake (~60% EU institutional procurement 2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner type\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003cth\u003e2024 metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSuppliers\u003c\/td\u003e\n\u003ctd\u003eAPI\/raw materials\u003c\/td\u003e\n\u003ctd\u003eEU GMP\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCRO\/CDMO\u003c\/td\u003e\n\u003ctd\u003eTrials\/scale-up\u003c\/td\u003e\n\u003ctd\u003e$66B\/$23B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulators\u003c\/td\u003e\n\u003ctd\u003eApprovals\u003c\/td\u003e\n\u003ctd\u003e210 days\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistributors\u003c\/td\u003e\n\u003ctd\u003eMarket reach\u003c\/td\u003e\n\u003ctd\u003eBaltics\/CEE; tenders 60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA comprehensive Business Model Canvas for Olainfarm detailing nine BMC blocks—customer segments, value propositions, channels, customer relationships, revenue streams, key resources, key activities, key partners, and cost structure—reflecting real-world pharmaceutical operations, competitive advantages, and linked SWOT insights, ideal for investor presentations, strategic planning, and validation of business decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page, editable Business Model Canvas for Olainfarm that condenses its pharma strategy into a clean snapshot, saving hours on structuring and enabling fast collaboration, comparisons, and board-ready summaries to quickly resolve strategy alignment and operational pain points.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDrug discovery and formulation R\u0026amp;D\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRational design and reformulation at Olainfarm target improved efficacy, bioavailability and patient adherence through lead-optimization and novel excipient strategies. The R\u0026amp;D portfolio prioritizes cardiovascular, CNS and anti-infective therapies aligned with regional therapeutic gaps. Robust analytical development validates stability and bioequivalence across formulations. Scaled tech-transfer protocols ready validated dossiers and processes for GMP production and commercial launch.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical, bioequivalence, and medical affairs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eClinical and bioequivalence studies (typically n=24–36 for crossover BE trials) generate the PK\/efficacy evidence required for approvals and label claims.\u003c\/p\u003e\n\u003cp\u003eMedical affairs drives publications, HCP education, and proactive safety communications to support uptake and prescribing.\u003c\/p\u003e\n\u003cp\u003ePharmacovigilance maintains continuous post‑launch benefit–risk monitoring and regulatory reporting (PSURs\/periodic reports as required in 2024), while generated evidence underpins tender bids and market access dossiers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGMP manufacturing and scale-up\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAs of 2024 Olainfarm operates GMP-certified in-house facilities producing finished products, APIs and intermediates, enabling vertical control of quality and supply. Continuous process optimization has raised yields and lowered unit costs across key lines. Rigorous QA\/QC, validation and batch release protocols preserve integrity for domestic and export markets. Capacity planning aligns product mix with export demand and regulatory timelines.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory affairs and market access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRegulatory affairs maintain dossiers, variations and renewals to keep licenses current across Olainfarm’s over 60 markets (2024), securing uninterrupted supply. Pricing strategies, HTA submissions and tender preparation drive reimbursement and public procurement access. Serialization and compliance programs meet local mandates, while active lifecycle management sustains product competitiveness and margin protection.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarkets: over 60 (2024)\u003c\/li\u003e\n\u003cli\u003eFocus: dossiers, variations, renewals\u003c\/li\u003e\n\u003cli\u003eAccess: pricing, HTA, tenders\u003c\/li\u003e\n\u003cli\u003eCompliance: serialization, local mandates\u003c\/li\u003e\n\u003cli\u003eStrategy: lifecycle management\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercialization and channel management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eField force promotion targets HCPs and hospital buyers to drive prescription uptake and tender wins, while brand and category marketing bolster OTC and supplement visibility and consumer preference. Demand planning and S\u0026amp;OP coordinate production and inventory to match channel demand and reduce stockouts. Digital engagement expands awareness, supports patient adherence and feeds real-time market insights.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eField force: HCPs \u0026amp; hospital buyers\u003c\/li\u003e\n\u003cli\u003eMarketing: OTC \u0026amp; supplements\u003c\/li\u003e\n\u003cli\u003eS\u0026amp;OP: align supply with channels\u003c\/li\u003e\n\u003cli\u003eDigital: awareness \u0026amp; adherence\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eR\u0026amp;D-led reformulations; BE trials n=24–36; approvals in \u0026gt;60 markets; GMP production \u0026amp; S\u0026amp;OP supply\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eR\u0026amp;D focuses on lead optimization and reformulation for cardiovascular, CNS and anti‑infective portfolios with BE trials typically n=24–36. Clinical, regulatory and PV sustain approvals and post‑launch safety across over 60 markets (2024). GMP in‑house production, S\u0026amp;OP and field force drive supply, tenders and HCP uptake.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eActivity\u003c\/th\u003e\n\u003cth\u003e2024 metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket reach\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;60 markets\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBE trial size\u003c\/td\u003e\n\u003ctd\u003en=24–36\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Document Unlocks After Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe Olainfarm Business Model Canvas you’re previewing is the actual deliverable, not a mockup or teaser. When you purchase, you’ll receive this exact file—complete, editable and formatted—ready for use. The same document will be provided in Word and Excel formats for immediate download.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eesources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGMP-certified plants and laboratories\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGMP-certified plants and laboratories enable Olainfarm to produce cost-efficient, regulatory-compliant medicines, supporting product margins and contract manufacturing revenue streams. QC laboratories perform release testing and multi-year stability programs that meet EU GMP standards, underpinning regulatory approvals and market access. Flexible production lines handle tablets, capsules, liquids and sterile forms, increasing SKU mix and operational agility. Capacity expansion in 2024 supported export growth—over 80% of sales go to international markets—boosting resilience and scaling opportunities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScientific and regulatory talent\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eChemists, formulators, clinicians and regulatory affairs experts drive Olainfarm’s pipeline progress by aligning development milestones with regulatory pathways. Cross-functional teams accelerate tech-transfer and approvals, shortening time-to-market and safeguarding manufacturing continuity. Pharmacovigilance and quality assurance specialists maintain safety and compliance across markets. Institutional know-how and legacy processes reduce development and regulatory risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual property and dossiers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eKnow-how, process IP and trademarks underpin Olainfarm’s differentiation, supporting proprietary API manufacture and brand protection across 40+ markets (2024). CTD dossiers and BE data enable multi-market registrations and quicker approvals. Documented methodologies for APIs and intermediates create B2B value and licensing income. Robust dossiers speed variations and line extensions, shortening time-to-market and lowering regulatory costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupply network and quality systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eQualified suppliers and audited partners ensure supply continuity and regulatory compliance for Olainfarm; EU serialization under the Falsified Medicines Directive and WHO Good Distribution Practice underpin product integrity. A certified QMS, validation protocols and serialization traceability protect against counterfeits and batch mix-ups. Robust logistics and cold-chain solutions preserve product quality and scale with new markets and SKUs.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAudited suppliers\u003c\/li\u003e\n\u003cli\u003eQMS \u0026amp; validation\u003c\/li\u003e\n\u003cli\u003eSerialization (EU FMD)\u003c\/li\u003e\n\u003cli\u003eCold-chain logistics\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBrands and customer relationships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOlainfarm leverages reputable product brands that support formulary and pharmacy uptake, reinforced by longstanding distributor and hospital partnerships that simplify market access.\u003c\/p\u003e\n\u003cp\u003eKOL engagement enhances credibility in targeted therapeutic areas while CRM-derived insights guide precise promotion and service offers to key customer segments.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eListed on Nasdaq Riga (OLF1R)\u003c\/li\u003e\n\u003cli\u003eEstablished distributor\/hospital networks\u003c\/li\u003e\n\u003cli\u003eKOL programs in core therapy areas\u003c\/li\u003e\n\u003cli\u003eCRM-driven targeted promotion\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGMP production fuels export growth: \u003cstrong\u003e80%+\u003c\/strong\u003e international sales, approvals in \u003cstrong\u003e40+\u003c\/strong\u003e markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGMP plants, QC labs and flexible lines support cost-efficient, multi-form manufacturing and enabled capacity expansion in 2024 to meet export demand—over 80% of sales are international. Chemists, regulatory and QA teams with CTD dossiers accelerate approvals across 40+ markets (2024). Audited suppliers, QMS, EU serialization and cold-chain logistics ensure compliance and supply continuity.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eResource\u003c\/th\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eExports\u003c\/td\u003e\n\u003ctd\u003eShare of sales\u003c\/td\u003e\n\u003ctd\u003e80%+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarkets\u003c\/td\u003e\n\u003ctd\u003eRegistered\u003c\/td\u003e\n\u003ctd\u003e40+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eListing\u003c\/td\u003e\n\u003ctd\u003eExchange\u003c\/td\u003e\n\u003ctd\u003eNasdaq Riga (OLF1R)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eV\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ealue Propositions\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-quality, EU-GMP pharmaceuticals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEU-GMP certified manufacturing at Olainfarm ensures rigorous quality controls and consistent safety and efficacy across production lines. Reliability from certified processes reduces supply disruptions for healthcare systems, supporting export operations to over 40 countries. Strong compliance builds trust with regulators and institutional buyers, reflected in sustained contract renewals. Patients gain access to dependable, quality-assured therapies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTherapy-focused portfolio in CVD, CNS, anti-infectives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDepth in CVD, CNS and anti-infectives leverages Olainfarm’s position as Latvia’s largest pharmaceutical manufacturer to support clinical relevance and therapeutic choice, addressing CVD which causes about 18 million deaths annually (WHO). Tailored formulations improve adherence and outcomes by simplifying dosing and formulation suitability. Clear evidence alignment and guideline-concordant data strengthen prescriber confidence, enabling hospitals to standardize protocols with proven options.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCost-effective generics and OTC solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCompetitive pricing of generics, typically 20–90% below originator prices, supports payer budgets and expands patient access. Efficient in-house manufacturing and scale reduce unit costs, lowering total treatment expenditure. Broad availability across retail channels meets rising OTC demand and drives volume. This value proposition underpins growth in tender-driven markets where price competitiveness wins contracts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAPIs and intermediates with technical support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAPIs and intermediates with technical support give B2B clients reliable supply and scalable processes, leveraging Olainfarm’s contract-manufacturing capabilities to shorten time-to-market; the global CDMO market surpassed $70 billion in 2024, underscoring demand for such services. Process know-how improves yields and regulatory compliance while custom specifications address partner requirements through joint development.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eReliable supply and scale\u003c\/li\u003e\n\u003cli\u003eHigher yields and compliance\u003c\/li\u003e\n\u003cli\u003eJoint development = faster launch\u003c\/li\u003e\n\u003cli\u003eCustom specs meet partner needs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStable supply and responsive service\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eForecast-driven planning and safety stocks reduce stock-outs, enabling Olainfarm, an EU GMP-certified Latvian manufacturer supplying to over 30 countries in 2024, to meet demand reliably. Fast regulatory and medical teams deliver expedited responses to customer issues, while robust post-market surveillance maintains product safety and compliance. High service levels underpin long-term contracts and repeat procurement.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eForecasting: reduced stock-outs\u003c\/li\u003e\n\u003cli\u003eRegulatory: rapid responses\u003c\/li\u003e\n\u003cli\u003eSafety: continuous post-market surveillance\u003c\/li\u003e\n\u003cli\u003eContracts: service-driven retention\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEU-GMP generics and CDMO services drive affordable supply to 40+ countries, tapping $70B market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEU-GMP manufacturing ensures quality and reliable supply to 40+ countries in 2024, supporting export contracts and patient access. Generic pricing 20–90% below originators reduces payer costs while CDMO\/API services tap a $70B global market (2024). Therapeutic focus on CVD, CNS and anti-infectives aligns with guideline needs and high unmet demand.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eExport countries\u003c\/td\u003e\n\u003ctd\u003e40+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCDMO market\u003c\/td\u003e\n\u003ctd\u003e$70B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGeneric discount\u003c\/td\u003e\n\u003ctd\u003e20–90%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Relationships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical detailing and scientific engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRegular HCP interactions share evidence and product updates through targeted medical detailing to maintain prescribing confidence and safety. CME programs and symposia deepen therapeutic knowledge and clinician loyalty across key specialties. Digital channels—webinars, MSL emails and portals—supplement in-person calls for broader reach. Global pharma sales reached $1.67 trillion in 2023 (IQVIA), highlighting market scale.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKey account management for hospitals and tenders\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDedicated key-account teams (20+ KAMs) coordinate hospital bids and contracts to streamline tender wins. Service-level agreements secure performance and supply, achieving \u0026gt;98% on-time delivery across hospital channels. Health-economic support and pharmacoeconomic dossiers strengthen value cases and can reduce price pressure by 10–15%. Deeper relationships lifted contract renewal rates to about 85% in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDistributor enablement and joint planning\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCo-marketing, distributor training, and secure data sharing boost sell-out by improving demand visibility and execution at retail. Joint business plans align incentives and targets through shared KPIs and quarterly milestones. Inventory and promotional support raise on-shelf availability and reduce stockouts. Regular performance reviews using sales and service metrics optimize execution and channel ROI.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTechnical support for B2B clients\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTechnical support for B2B clients provides API and intermediate customers with formulation and process assistance, streamlined change controls and documentation to ease regulatory compliance, and rapid 24\/7 troubleshooting to protect production uptime; collaboration drives repeat business across Olainfarm's 40+ export markets.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAPI\/intermediates support\u003c\/li\u003e\n\u003cli\u003eChange controls \u0026amp; documentation\u003c\/li\u003e\n\u003cli\u003e24\/7 rapid troubleshooting\u003c\/li\u003e\n\u003cli\u003eCollaboration → repeat business; 40+ countries\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient and pharmacy engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePatient and pharmacy engagement leverages adherence tools and targeted education to improve clinical outcomes and reduce therapy lapses; Olainfarm reported expanded pharmacist training programs in 2024 that increased recommendation rates and OTC cross-sales. Consumer care lines handle OTC queries and triage, while loyalty and automated reminder services drive repeat purchase and Rx refill adherence. \u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAdherence tools: improved outcomes\u003c\/li\u003e\n\u003cli\u003ePharmacist programs: higher recommendation rates\u003c\/li\u003e\n\u003cli\u003eConsumer care lines: OTC support\u003c\/li\u003e\n\u003cli\u003eLoyalty\/reminders: repeat purchases\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsistent pharma supply: \u003cstrong\u003e\u0026gt;98%\u003c\/strong\u003e on-time, ~85% renewals, $1.67T market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRegular HCP engagement (medical detailing, CME, MSLs) sustains prescribing confidence; \u0026gt;98% hospital on-time delivery and ~85% contract renewal in 2024. Digital channels and pharmacist programs boosted OTC cross-sales and adherence; global pharma market $1.67T (2023). Technical B2B support across 40+ export markets drives repeat contracts.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOn-time delivery\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;98%\u003c\/td\u003e\n\u003ctd\u003eService reliability\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eContract renewal\u003c\/td\u003e\n\u003ctd\u003e~85% (2024)\u003c\/td\u003e\n\u003ctd\u003eCustomer retention\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExport markets\u003c\/td\u003e\n\u003ctd\u003e40+\u003c\/td\u003e\n\u003ctd\u003eRepeat B2B sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal market\u003c\/td\u003e\n\u003ctd\u003e$1.67T (2023)\u003c\/td\u003e\n\u003ctd\u003eMarket scale\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehannels\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWholesalers and pharmacy distribution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNational wholesalers ensure broad retail coverage across Latvia's population of around 1.87 million, enabling Olainfarm products to reach urban and regional pharmacies. Pharmacy chains drive visibility and planogram placement, securing shelf space in key outlets. Promotions and POS materials lift OTC sales during campaigns, increasing velocity at the point of sale. Real-time data feeds improve demand planning and reduce stockouts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospital and public procurement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTender participation secures volume contracts within a public procurement market that represents about 14% of EU GDP (≈€2 trillion), making hospital tenders a key channel for Olainfarm. Clinical and economic dossiers aligned with HTA and hospital formulary criteria increase award likelihood. Reliable logistics and on-time delivery meet strict contractual SLAs, while post-award customer service sustains contract performance and renewal.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect B2B sales to manufacturers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDirect B2B sales to manufacturers rely on technical sales teams to sell APIs and intermediates, supported by samples, DMFs and audits that shorten qualification cycles; in 2024 the global API market was estimated at about 172 billion USD, underscoring demand. Long-term supply agreements stabilize volumes and cash flow, while joint development projects increase customer stickiness and raise switching costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational distributors and agents\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eInternational distributors and agents help Olainfarm navigate local regulation and market nuances, accelerating registrations and market access across CEE and key export regions in 2024.\u003c\/p\u003e\n\u003cp\u003ePerformance-based agreements link payments to sales milestones and market share, aligning partner incentives with Olainfarm’s growth targets.\u003c\/p\u003e\n\u003cp\u003eShared market insights from partners refine portfolio fit and launch sequencing, improving ROI on new product introductions.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLocal regulatory expertise\u003c\/li\u003e\n\u003cli\u003eCEE and export expansion 2024\u003c\/li\u003e\n\u003cli\u003ePerformance-linked contracts\u003c\/li\u003e\n\u003cli\u003eData-driven portfolio optimization\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital and remote engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eeDetailing, webinars and HCP portals extend Olainfarm’s reach by enabling targeted, compliant remote interactions; e-commerce where permitted increases OTC accessibility; self-service documentation accelerates B2B order processing; analytics continuously refine campaign ROI and HCP segmentation.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eeDetailing: targeted HCP outreach\u003c\/li\u003e\n\u003cli\u003eWebinars\/portals: scalable education\u003c\/li\u003e\n\u003cli\u003eE‑commerce: OTC sales channel\u003c\/li\u003e\n\u003cli\u003eSelf‑service: faster B2B transactions\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNational wholesalers, pharmacies and tenders unlock Latvia reach and USD172bn API export growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNational wholesalers and pharmacy chains secure nationwide retail reach across Latvia (pop. 1.87M) and boost OTC velocity via promotions and POS. Tender wins target public procurement (~€2tn market, ~14% EU GDP) for hospital volumes. B2B\/API sales tap a global API market ~USD172bn (2024), while distributors, eDetailing and e‑commerce accelerate export and HCP access.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003e2024 metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRetail reach\u003c\/td\u003e\n\u003ctd\u003eLatvia pop 1.87M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTenders\u003c\/td\u003e\n\u003ctd\u003e€2tn public procurement\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAPI market\u003c\/td\u003e\n\u003ctd\u003eUSD172bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Segments\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospitals and healthcare institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHospitals and healthcare institutions procure Rx products primarily through competitive tenders and framework contracts, with European Commission data indicating tenders cover roughly two-thirds of hospital medicines in many EU markets. They prioritize clinical evidence, accredited quality standards and assured supply—stock-outs in 2022–24 spikes heightened focus on reliable suppliers. Standardization and patient safety drive formularies, and established long-term partnerships significantly increase contract renewal probability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePhysicians and specialists\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePrescribers in cardiology, neurology and infectious disease prioritize proven efficacy and safety, with cardiology driven by cardiovascular disease causing 17.9 million deaths annually and neurology affecting roughly 1 billion people worldwide. Guideline alignment (ESC, AHA, EAN) strongly shapes choices. Education, peer-to-peer training and samples increase adoption and adherence. Trust in clinical data and local KOLs materially influences prescribing behavior.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmacies and retail chains\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePharmacies and retail chains are the primary channel for Olainfarm's OTC and supplement sales, driving consumer reach and volume.\u003c\/p\u003e\n\u003cp\u003eProminent shelf presence and pharmacist recommendation strongly influence purchase decisions, increasing conversion and repeat buy rates.\u003c\/p\u003e\n\u003cp\u003eConsistent supply, competitive trade terms and promotional programs with chains secure stocking priority and boost recommendation rates from pharmacy staff.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatients and consumers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cppatients and consumers are end-users of olainfarm rx otc supplement portfolio who prioritize affordability consistent availability simple dosing to support daily use. education-linked interventions matter: estimates medication adherence for chronic conditions averages around so patient education directly improves outcomes. strong brand trust drives repeat purchases loyalty especially in supplements.\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\u003cli\u003eEnd-users: Rx, OTC, supplements\u003c\/li\u003e\u003cli\u003ePriorities: affordability, availability, ease-of-use\u003c\/li\u003e\u003cli\u003eAdherence: WHO ~50% for chronic meds\u003c\/li\u003e\u003cli\u003eDriver: brand trust → loyalty\u003c\/li\u003e\n\u003c\/ppatients\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharma manufacturers and B2B buyers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cppharma manufacturers and b2b buyers purchase active pharmaceutical ingredients intermediates from olainfarm for formulation supply chains often sourcing multiple grades volumes to meet demand technical support batch documentation regulatory dossiers are routinely required. consistency gmp compliance traceability decisive criteria strategic partnerships may extend co-development toll manufacturing global api market in\u003e\n\u003cp\u003e\u003c\/p\u003e\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePurchase focus: APIs \u0026amp; intermediates\u003c\/li\u003e\n\u003cli\u003eSupport needs: technical docs, regulatory dossiers\u003c\/li\u003e\n\u003cli\u003eDecisive: consistency, GMP compliance, traceability\u003c\/li\u003e\n\u003cli\u003ePartnerships: co-development, toll manufacturing\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/ppharma\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEU tenders cover \u003cstrong\u003e66%\u003c\/strong\u003e of hospital medicines; WHO adherence ~50%\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHospitals procure via tenders\/frameworks prioritizing quality and supply continuity; EU tenders cover ~66% of hospital medicines. Pharmacies drive OTC volume; pharmacist recommendation boosts conversion. Patients value affordability, availability and simple dosing; WHO adherence ~50% for chronic meds. API\/B2B buyers demand GMP, traceability; global API market ~185bn USD in 2024.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003eKey needs\u003c\/th\u003e\n\u003cth\u003e2024 metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals\u003c\/td\u003e\n\u003ctd\u003eQuality, supply\u003c\/td\u003e\n\u003ctd\u003e~66% tender share\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharmacies\u003c\/td\u003e\n\u003ctd\u003eShelf, recommendations\u003c\/td\u003e\n\u003ctd\u003eHigh OTC conversion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatients\u003c\/td\u003e\n\u003ctd\u003eAffordability, adherence\u003c\/td\u003e\n\u003ctd\u003eWHO adherence ~50%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAPI\/B2B\u003c\/td\u003e\n\u003ctd\u003eGMP, traceability\u003c\/td\u003e\n\u003ctd\u003eMarket ~185bn USD\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eost Structure\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eR\u0026amp;D and clinical expenditures\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDiscovery, formulation, and bioequivalence studies represent the primary R\u0026amp;D and clinical cost drivers for Olainfarm, requiring substantial lab, trial, and regulatory spending. Medical affairs and pharmacovigilance create ongoing operating expenses to support marketed products and safety reporting. Advancing the pipeline demands specialized talent in formulation science and clinical operations, increasing personnel costs. A disciplined portfolio focus—prioritizing high-margin generics and niche proprietary formulations—improves ROI.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRaw materials and energy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAPIs, excipients, solvents and utilities represent the largest raw-material and energy components in Olainfarm’s cost base; 2024 price volatility in APIs and energy drove the company to expand hedging and multi-year supplier contracts, while quality-driven sourcing raised inspection and compliance costs, and targeted efficiency projects (process optimization and energy-saving investments) have reduced raw-material and utility inflation pressures.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing, QA\/QC, and maintenance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGMP operations, validation and analytical testing form the core of Olainfarm’s manufacturing cost base, driving ongoing QA\/QC staffing and lab consumables. Regular equipment upkeep and calibrations maintain batch reliability and regulatory compliance. Capacity expansions trigger capex and tech-transfer costs for new lines. Continuous scrap reduction and yield improvements protect margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSales, marketing, and distribution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eField force, promotions and trade terms remain primary demand drivers for Olainfarm, while logistics, warehousing and mandatory serialization increase unit costs; international expansion further raises localization and regulatory expenses, and targeted digital spend complements in-person efforts to improve ROI.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eField force: direct sales coverage\u003c\/li\u003e\n\u003cli\u003ePromotions \u0026amp; trade terms: demand stimulation\u003c\/li\u003e\n\u003cli\u003eLogistics\/serialization: compliance cost\u003c\/li\u003e\n\u003cli\u003eLocalization: market entry expense\u003c\/li\u003e\n\u003cli\u003eDigital: supportive marketing spend\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory, compliance, and overhead\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRegulatory filings, mandatory audits and EU pharmacovigilance systems drive recurring compliance spend and require continuous investment in quality management to sustain market access for Olainfarm.\u003c\/p\u003e\n\u003cp\u003eIT, HR and administration scale with production and R\u0026amp;D; insurance and legal costs protect operations while corporate governance ensures compliance with EMA and EU requirements.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMandatory PV systems: EU\/EMA compliance\u003c\/li\u003e\n\u003cli\u003eAudits \u0026amp; filings: continuous recurring costs\u003c\/li\u003e\n\u003cli\u003eSupport functions: scalable OPEX\u003c\/li\u003e\n\u003cli\u003eInsurance \u0026amp; legal: risk mitigation\u003c\/li\u003e\n\u003cli\u003eGovernance: preserves market access\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eR\u0026amp;D, GMP and raw-material inflation squeeze margins; 2024 capex ~\u003cstrong\u003eEUR 18m\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eR\u0026amp;D\/clinical and GMP manufacturing are largest cost pools; 2024 R\u0026amp;D ran near 6% of revenue while API and energy inflation added ~8% to raw-materials costs. Sales force, promotions and serialization drive commercial unit costs; logistics and localization increased international launch spend. Capex for capacity and tech transfer reached about EUR 18m in 2024, with PV\/compliance as recurring OPEX.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCost item\u003c\/th\u003e\n\u003cth\u003e2024 metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e~6% rev\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAPI\/energy inflation\u003c\/td\u003e\n\u003ctd\u003e+8% Y\/Y\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapex\u003c\/td\u003e\n\u003ctd\u003e~EUR 18m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eevenue Streams\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrescription finished pharmaceuticals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePrescription finished pharmaceuticals form Olainfarm’s core revenue, anchored by cardiovascular, CNS and anti-infective portfolios. Sales flow primarily through hospital procurement and retail pharmacies, with public and private tenders securing volume. Tenders drive scale but exert pricing pressure on margins. Active lifecycle management, including line extensions and manufacturing efficiencies, sustains market share.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOTC medicines and food supplements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRetail-driven OTC medicines and food supplements deliver seasonal and brand-driven revenues, with Olainfarm leveraging pharmacy networks to capture peak Q1 and cold-season demand in 2024. Margins for branded OTCs typically reach 20–40% with targeted marketing and SKU promotion in 2024 campaigns. Consumer loyalty programs in 2024 increased repeat purchase frequency, while cross-selling expanded average basket size and ancillary sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAPIs and chemical intermediates\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eB2B sales of APIs and chemical intermediates supply manufacturers with reliable volumes, often under long-term contracts of 2–5 years that stabilize demand and cash flow. Technical service, regulatory documentation and supply-chain support drive stickiness and reduce partner risk. Custom development and toll-manufacturing projects typically command 10–25% premiums versus standard catalog pricing, boosting margin contribution.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract development and manufacturing services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCDMO projects monetize Olainfarm's excess capacity and regulatory expertise, generating fees across development, scale-up and commercial production and turning idle lines into revenue drivers. Long-term, sticky client relationships often convert single projects into multi-year engagements, improving visibility and cash flow. Higher plant utilization from CDMO work lifts gross margins and spreads fixed costs.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRevenue source: contract development and manufacturing\u003c\/li\u003e\n\u003cli\u003eFees: development, scale-up, production\u003c\/li\u003e\n\u003cli\u003eCustomer dynamics: multi-year, sticky engagements\u003c\/li\u003e\n\u003cli\u003eFinancial impact: utilization-driven margin expansion\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLicensing, out-licensing, and royalties\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOlainfarm monetizes dossiers, brands and territories through licensing and out-licensing agreements, leveraging partner distribution to accelerate market access in 2024. Royalties deliver recurring, low‑capex income streams while co-marketing deals extend commercial reach and local expertise. Risk-sharing licensing structures reduce upfront investment and support new product launches.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\u003c\/ul\u003e\n\u003cli\u003eMonetize dossiers\/brands\/territories\u003c\/li\u003e\n\u003cli\u003eRecurring royalties, low capex\u003c\/li\u003e\n\u003cli\u003eCo-marketing expands reach\u003c\/li\u003e\n\u003cli\u003eRisk-sharing for launches\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharma mix: OTC 20-40% margins, B2B contracts +10-25%, CDMO \u0026amp; licensing expand margins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePrescription Rx (core) via hospitals\/retail; tenders drive volume but compress margins. Branded OTCs\/food supplements: seasonal Q1\/cold demand, margins 20–40% in 2024. B2B APIs: long‑term contracts 2–5 yrs, premiums 10–25%. CDMO drives utilization and margin expansion; licensing\/royalties provide recurring, low‑capex income.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSource\u003c\/th\u003e\n\u003cth\u003eKey metrics\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOTC margins\u003c\/td\u003e\n\u003ctd\u003e20–40% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eB2B contracts\u003c\/td\u003e\n\u003ctd\u003e2–5 yrs; +10–25% price prem.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"PESTEL Analysis","offers":[{"title":"Default Title","offer_id":58098166202716,"sku":"olainfarm-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0938\/8127\/0620\/files\/olainfarm-business-model-canvas.png?v=1781802497","url":"https:\/\/pestel-analysis.com\/products\/olainfarm-business-model-canvas","provider":"PESTEL ANALYSIS","version":"1.0","type":"link"}